搜尋結果
BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek[2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ...
- 2008; 15 years ago
- Mainz, Germany
- 4,530 (2022)
- Biotechnology
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer
- Comirnaty
- mRNA
其他人也問了
Where is biontech based?
Why did the European Investment Bank sign a deal with biontech?
Is biontech a publicly traded company?
Who is the Board of biontech?
Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, , .
On 12 July Foxconn Technology and TSMC announced that they had reached final agreements with Fosun Pharma to each purchase 5 million doses of the Pfizer-BioNTech COVID-19 vaccine. Combined, the two deals would include a total of 10 million vaccines, which will be donated to Taiwan's CDC for Taiwan's domestic vaccination plan.
References. External links. Uğur Şahin ( Turkish: [uˈuɾ ʃaː.hin]; born 19 September 1965 [3]) is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. [4] [5] His main fields of research are cancer research and immunology. [6]
RNA vaccines are the first COVID‑19 vaccines to be authorized in the United Kingdom, the United States, and the European Union. [56] [57] Authorized vaccines of this type are the Pfizer–BioNTech [58] [59] [60] and Moderna vaccines. [61] [62] The CVnCoV RNA vaccine from CureVac failed in clinical trials.
Pfizer-BioNTech COVID-19 vaccine. The Pfizer-BioNTech partnership submitted an EUA request to the FDA for the mRNA vaccine BNT162b2 (active ingredient tozinameran) on 20 November 2020.
